Figure 1
Survival outcomes with rituximab-ABVD in classical Hodgkin lymphoma. (A) EFS and overall survival after treatment initiation, estimated by the Kaplan-Meier method. An event is defined as relapse, progression, or death. (B) EFS in patients with early unfavorable or advanced disease. (C) EFS according to the International Prognostic Score (IPS) in patients with advanced disease. (D) EFS according to the interim PET result.

Survival outcomes with rituximab-ABVD in classical Hodgkin lymphoma. (A) EFS and overall survival after treatment initiation, estimated by the Kaplan-Meier method. An event is defined as relapse, progression, or death. (B) EFS in patients with early unfavorable or advanced disease. (C) EFS according to the International Prognostic Score (IPS) in patients with advanced disease. (D) EFS according to the interim PET result.

Close Modal

or Create an Account

Close Modal
Close Modal